Healthcare divestitures
69 completed divestitures by healthcare sellers were disclosed in SEC 8-K filings up to 6 November 2026: 31 in 2026 so far and 38 in 2025. 53 stated a price, totalling $19bn; the largest was Solventum Corp's sale of Solventum Purification & Filtration business for $4bn. The sector is the seller's SEC industry code.
The 5 largest healthcare divestitures.
By the value stated in the filing, before adjustments, across every year in the tracker.
| Filed | Seller | Business sold | Buyer | Disclosed value | Filing |
|---|---|---|---|---|---|
| 2025-09-02 | Solventum Corp (SOLV) | Solventum Purification & Filtration businessWhat the filing says"Solventum (NYSE: SOLV) today announced it has completed the sale of its Purification & Filtration business ("P&F") to Thermo Fisher Scientific Inc. (NYSE: TMO) ("Thermo Fisher") for $4.0 billion in cash before customary adjustments." | Thermo Fisher Scientific Inc. | $4bn | SEC 8-K exhibit |
| 2025-02-03 | BAXTER INTERNATIONAL INC (BAX) | Vantive Health LLCWhat the filing says"On January 31, 2025 (the " Closing Date "), Baxter International Inc. (the " Company ") completed the previously announced sale of all issued and outstanding equity interests of Vantive Health LLC, a Delaware limited liability company (the " KidneyCo "), Vantive Mexico LLC, a Delaware limited liability company (the " US-Mexico Holdco "), Gambro Renal Products, Inc., a Delaware corporation (the " Gambro Subsidiary "), RTS Worldwide Holdings Inc., a Delaware corporation (the " RTS Holdco " and, together with KidneyCo" | CP Spruce Holdings, S.C.Sp | $3.8bn | SEC 8-K |
| 2026-07-13 | Edgewise Therapeutics, Inc. (EWTX) | Edgewise Therapeutics muscular dystrophy program (sevasemten)What the filing says"On July 10, 2026, Edgewise Therapeutics, Inc. (the "Company") completed the previously announced acquisition of the Company's sevasemten compound and certain other related assets collectively constituting the Company's muscular dystrophy program (the "Program") by Servier Pharmaceuticals LLC and Les Laboratoires Servier (together, the "Buyers", and such transaction, the "Transaction"), pursuant to the terms and conditions of the previously announced Asset Purchase Agreement by and among the Company and the Buyers." | Servier | $1.55bn | SEC 8-K |
| 2026-08-03 | TELEFLEX INC (TFX) | Original Equipment Manufacturing and Development Services businessWhat the filing says"On August 3, 2026 (the " Closing Date "), Teleflex Incorporated (the " Company ") completed the previously announced sale of its Original Equipment Manufacturing and Development Services business (the " OEM Business ") to Lotus US Bidco Inc., a Delaware corporation (the " OEM Purchaser "), pursuant to the Equity Purchase Agreement, dated December 9, 2025 (the " OEM Agreement "), by and between the Company and the OEM Purchaser (the " OEM Transaction ")" | Lotus US Bidco Inc. | $1.5bn | SEC 8-K |
| 2026-03-31 | BrightSpring Health Services, Inc. (BTSG) | ResCare Community LivingWhat the filing says"BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based pharmacy and health services for complex populations, today announced the completed sale of ResCare Community Living to Sevita, a leading provider of home and community-based specialty health care." | National Mentor Holdings, Inc. | $835M | SEC 8-K exhibit |
31 healthcare divestitures in 2026 so far.
| Filed | Seller | Business sold | Buyer | Disclosed value | Filing |
|---|---|---|---|---|---|
| 2026-11-05 | Inogen Inc (INGN) | U.S. oxygen rental businessWhat the filing says"On November 2, 2026, Inogen, Inc. ("Inogen" or the "Company") completed the previously announced sale of the United States oxygen rental business (the "Rental Business") to Rotech Healthcare Inc. ("Rotech"), pursuant to the terms of the Asset Purchase Agreement, dated as of September 29, 2026 (the "Asset Purchase Agreement")." On the price: "The aggregate purchase price is estimated at up to approximately $24.8 million based on the inventory and patient records to be transferred and is subject to post-closing reconciliation, and payable in six installments." | Rotech Healthcare Inc. | $24.8M | SEC 8-K |
| 2026-11-02 | Theriva Biologics, Inc. (TOVX) | antibiotic-degrading enzyme portfolio (SYN-004 ribaxamase, SYN-007 and SYN-006 assets)What the filing says"On October 30, 2026 (the "Effective Date"), Theriva Biologics, Inc. (the "Company") entered into an Asset Purchase and Sale Agreement (the "Purchase Agreement") with Biossil Labs Inc., a corporation organized under the laws of Canada (the "Biossil"), pursuant to which the Company sold to Biossil, and Biossil purchased from the Company, the Company's assets exclusively relating to SYN-004 (ribaxamase), the Company's oral β-lactamase product candidate, including its improvements, modifications and reformulations, including SYN-007 (collectively, "Ribaxamase"), as well as certain assets exclusively related to SYN-006, the Company's carbapenemase product candidate (collectively, the "Purchased Assets")." On the price: "In consideration for the Purchased Assets, Biossil paid the Company an upfront payment of $350,000 at the Closing, which is non-refundable and non-creditable against other amounts payable under the Purchase Agreement." | Biossil Labs Inc. | Not disclosed | SEC 8-K |
| 2026-10-19 | Medtronic plc (MDT) | Spin-off: MiniMed Group, Inc.What the filing says"GALWAY, Ireland, October 15, 2026 - Medtronic plc (Medtronic; NYSE: MDT) today announced the completion of its separation of MiniMed Group, Inc. (MiniMed; Nasdaq: MMED)." | Not named in this filing | Not disclosed | SEC 8-K exhibit |
| 2026-10-06 | BeyondSpring Inc. (BYSI) | BeyondSpring Ltd. and its subsidiaries, including Dalian Wanchunbulin PharmaceuticalsWhat the filing says"Pursuant to the Agreement, the Company agreed to sell to the Investor all of its ownership interests in BeyondSpring Ltd., including its direct and indirect subsidiaries and related investments (the "Sale"), in exchange for noncash consideration consisting principally of (i) a license to use certain data generated in connection with the DUBLIN-4 clinical trial and (ii) the Investor's commitment to fund Bulin's conduct of the trial and the generation and delivery of such data." | Biolin Investment Limited | Not disclosed | SEC 8-K |
| 2026-09-17 | Surgery Partners, Inc. (SGRY) | Mountain View Hospital and Idaho Falls Community HospitalWhat the filing says"On September 14, 2026 , Surgery Partners, Inc. (the "Company"), through certain of its subsi diaries, completed the disposition of Moun tain View Hospital, LLC ("MVH") and Idaho Falls Community Hospital, LLC ("IFCH") (collectively, the "Disposed Business"), to Intermountain Health." | Intermountain Health | $797M | SEC 8-K |
| 2026-09-14 | Quince Therapeutics, Inc. (QNCX) | Quince Therapeutics SpA and AIDE/eDSP assetsWhat the filing says"On September 8, 2026, Quince Therapeutics, Inc. (the "Company") completed the sale of (i) all of the issued and outstanding equity interests of the subsidiary Quince Therapeutics SpA ("Quince SpA"), (ii) certain intellectual property owned by the Company relating to the Company's proprietary Autologous Intracellular Drug Encapsulation ("AIDE") technology for the treatment of Ataxia-Telangiectasia ("A-T") through its encapsulated dexamethasone sodium phosphate encapsulated in patient's own red blood cells ("eDSP") p" | Ayma Therapeutics, Inc. | $450K | SEC 8-K |
| 2026-09-08 | International Stem Cell CORP (ISCO) | Lifeline Cell Technology, LLCWhat the filing says"Exhibit 99.1 INTERNATIONAL STEM CELL CORPORATION Unaudited Pro Forma Financial Statements On September 1, 2026, International Stem Cell Corporation (the Company ) completed the sale of 100% of the membership interests of its wholly-owned subsidiary Lifeline Cell Technology, LLC ( LCT ), to American Type Culture Collection, Inc. ( ATCC ) pursuant to the Membership Interest Purchase Agreement (the MIPA ) dated July 10, 2026, for an adjusted purchase price of $25,250,000 (base purchase price of $25,000,000 plus a fixe" | American Type Culture Collection, Inc. | $25.3M | SEC 8-K exhibit |
| 2026-08-21 | ELUTIA INC. (ELUT) | SimpliDerm human acellular dermal matrix businessWhat the filing says"(Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced it completed the sale of its SimpliDerm human acellular dermal matrix business to Cellution Biologics Inc. for total consideration of up to $11 million" | Cellution Biologics Inc. | $11M | SEC 8-K exhibit |
| 2026-08-13 | MACROGENICS INC (MGNX) | GMP drug substance manufacturing operationsWhat the filing says"In July, MacroGenics announced the completion of the sale of its GMP drug substance manufacturing operations to Bora Pharmaceuticals Co., Ltd. and Bora Biologics USA, LLC (collectively, Bora) for a previously disclosed base purchase price of $122.5 million" | Bora Pharmaceuticals Co., Ltd. and Bora Biologics USA, LLC | $123M | SEC 8-K exhibit |
| 2026-08-03 | TELEFLEX INC (TFX) | Original Equipment Manufacturing and Development Services businessWhat the filing says"On August 3, 2026 (the " Closing Date "), Teleflex Incorporated (the " Company ") completed the previously announced sale of its Original Equipment Manufacturing and Development Services business (the " OEM Business ") to Lotus US Bidco Inc., a Delaware corporation (the " OEM Purchaser "), pursuant to the Equity Purchase Agreement, dated December 9, 2025 (the " OEM Agreement "), by and between the Company and the OEM Purchaser (the " OEM Transaction ")" | Lotus US Bidco Inc. | $1.5bn | SEC 8-K |
| 2026-07-31 | VASO Corp (VASO) | NetWolves Network Services LLCWhat the filing says"On July 31, 2026, pursuant to the Purchase Agreement described in Item 1.01 of this Current Report on Form 8-K, Buyer purchased all of the issued and outstanding membership interests of NetWolves from Vaso and VasoTech." | COEO Solutions, LLC | $14.5M | SEC 8-K |
| 2026-07-13 | Edgewise Therapeutics, Inc. (EWTX) | Edgewise Therapeutics muscular dystrophy program (sevasemten)What the filing says"On July 10, 2026, Edgewise Therapeutics, Inc. (the "Company") completed the previously announced acquisition of the Company's sevasemten compound and certain other related assets collectively constituting the Company's muscular dystrophy program (the "Program") by Servier Pharmaceuticals LLC and Les Laboratoires Servier (together, the "Buyers", and such transaction, the "Transaction"), pursuant to the terms and conditions of the previously announced Asset Purchase Agreement by and among the Company and the Buyers." | Servier | $1.55bn | SEC 8-K |
| 2026-07-07 | CareDx, Inc. (CDNA) | Lab Products businessWhat the filing says"Nasdaq CDNA) - The Transplant Company , a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high value healthcare solutions for transplant patients and caregivers, today announced the closing of the previously announced sale of its Lab Products business to Eurobio Scientific" On the price: "The aggregate purchase price received by the Company was $171.7 million in cash, subject to certain customary adjustments specified in the Purchase Agreement for working capital, cash and indebtedness." | Eurobio Scientific S.A. | $172M | SEC 8-K exhibit |
| 2026-07-01 | CUMBERLAND PHARMACEUTICALS INC (CPIX) | Cumberland Pharmaceuticals branded product portfolioWhat the filing says"Under the terms of the agreement, Apotex has acquired Cumberland's line of branded pharmaceuticals for cash consideration of $100 million funded at closing, which followed approval by Cumberland's shareholders." | Apotex Inc. | $100M | SEC 8-K exhibit |
| 2026-06-05 | VSEE HEALTH, INC. (VSEE) | VSee Lab, Inc.What the filing says"Pursuant to the Purchase Agreement, Mr. Chen agreed to purchase, and the Company agreed to sell to Mr. Chen, on the May 31, 2026 (the "Closing Date"), all of the equity securities of VSee Lab (the "VSee Lab Stock"), free and clear of all liens and encumbrances." | Milton Chen | Not disclosed | SEC 8-K exhibit |
| 2026-06-01 | COMMUNITY HEALTH SYSTEMS INC (CYH) | CHS Northwest Arkansas hospitalsWhat the filing says"On June 1, 2026, CHS/Community Health Systems, Inc. ("CHS"), a wholly-owned subsidiary of Community Health Systems, Inc. (the "Company"), completed the transactions contemplated by that certain Asset Purchase Agreement dated as of March 5, 2026 (the "Purchase Agreement"), with Freeman-Oak Hill Health System, d/b/a Freeman Health System (the "Purchaser")." | Freeman Health System | $110M | SEC 8-K |
| 2026-05-12 | Corium Therapeutics Holdings, LLC | GPC Commave Holding, LLC and Commave Sub, LLCWhat the filing says"On May 12, 2026, pursuant to the Purchase Agreement, the Company completed the acquisition (the " Closing ") of (i) all of the issued and outstanding limited liability interests of GPC Commave Holding, LLC, a Delaware limited liability company (" GPC ") from Commave Seller, and (ii) all of the issued and outstanding limited liability interests of Commave Sub, LLC, a Delaware limited liability company from Corium Seller." | Collegium Pharmaceutical, Inc. | $650M | SEC 8-KFiled by the buyer |
| 2026-05-07 | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | CDMO and Cell Solutions businessesWhat the filing says"Divestiture Update On May 6, 2026, the Company completed the previously announced divestiture of the CDMO and Cell Solutions businesses to GI Partners" | GI Partners | Not disclosed | SEC 8-K exhibit |
| 2026-04-30 | PERRIGO Co plc (PRGO) | Perrigo Dermacosmetics businessWhat the filing says"Perrigo Company plc (NYSE: PRGO) ("Perrigo" or the "Company"), a leading global provider of consumer health products, today announced that it has completed the previously announced sale of its branded Dermacosmetics business to Karo Healthcare ("Karo") for total consideration of up to €332.6 million." | Karo Healthcare AB | Not disclosed | SEC 8-K exhibit |
| 2026-04-21 | Celularity Inc. (CELU) | Celularity regenerative biomaterials businessWhat the filing says"On April 17, 2026, the Company completed the transactions contemplated by the License Agreement, pursuant to which the Company acquired an exclusive license to the Business, on the terms described under Item 1.01 of this Current Report on Form 8-K, which description is incorporated herein by reference." | NexGel, Inc. | $13.3M | SEC 8-KFiled by the buyer |
| 2026-04-20 | ANAPTYSBIO, INC (ANAB) | Spin-off: First Tracks Biotherapeutics, Inc.What the filing says"AnaptysBio, Inc. (Nasdaq: ANAB), a royalty management company, today announced the completion of its spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business." | Not named in this filing | Not disclosed | SEC 8-K exhibit |
| 2026-04-14 | Assertio Holdings, Inc. (ASRT) | Assertio INDOCIN, SPRIX, SYMPAZAN, CAMBIA, ZIPSOR and OTREXUP product franchisesWhat the filing says"On April 8, 2026, the Company also completed the sale (the " Asset Sale ") of its right, title and interest in and to the INDOCIN®, SPRIX®, SYMPAZAN®, CAMBIA®, ZIPSOR® and the recently decommercialized OTREXUP® franchises of products (collectively, the " Products ") to Cosette pursuant to the Asset Purchase Agreement, for an aggregate purchase price of $35,000,000 in cash, with the potential for additional deferred amounts consisting of (i) in respect of SYMPAZAN, INDOCIN and OTREXUP, net sales-based milestone paym" | Cosette Pharmaceuticals, Inc. | $35M | SEC 8-K |
| 2026-04-07 | Ginkgo Bioworks Holdings, Inc. (DNA) | Ginkgo Biosecurity, LLCWhat the filing says"On April 3, 2026, Ginkgo Bioworks, Inc. (the "Seller"), a wholly owned subsidiary Ginkgo Bioworks Holdings, Inc. (the "Company") completed the previously announced transaction (the "Transaction") with Tower Biosecurity, Inc. also known as Perimeter Systems, Inc. (the "Purchaser") pursuant to the Stock Purchase Agreement, dated as of February 26, 2026 (the "Purchase Agreement"), by and among the Seller, the Company, the Purchaser and Ginkgo Biosecurity, LLC ("Biosecurity")." | Tower Biosecurity, Inc. | Not disclosed | SEC 8-K |
| 2026-04-01 | COMMUNITY HEALTH SYSTEMS INC (CYH) | Crestwood Medical CenterWhat the filing says"On April 1, 2026, CHS/Community Health Systems, Inc. ("CHS"), a wholly-owned subsidiary of Community Health Systems, Inc. (the "Company"), completed the transaction contemplated by that certain Asset Purchase Agreement dated as of January 20, 2026 (the "Purchase Agreement"), with The Health Care Authority of the City of Huntsville, d/b/a Huntsville Hospital Health System (the "Purchaser"), the entry into which Purchase Agreement was previously disclosed on a Current Report on Form 8-K filed by the Company with the " | The Health Care Authority of the City of Huntsville | $459M | SEC 8-K |
| 2026-03-31 | BrightSpring Health Services, Inc. (BTSG) | ResCare Community LivingWhat the filing says"BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based pharmacy and health services for complex populations, today announced the completed sale of ResCare Community Living to Sevita, a leading provider of home and community-based specialty health care." | National Mentor Holdings, Inc. | $835M | SEC 8-K exhibit |
| 2026-03-31 | ORAMED PHARMACEUTICALS INC. (ORMP) | Oratech Pharma, Inc.What the filing says"On March 25, 2026, Lifeward completed its acquisition of Oratech in accordance with the terms of the Share Purchase Agreement." | Lifeward Ltd. | Not disclosed | SEC 8-K |
| 2026-03-13 | IMAC Holdings, Inc. | Ignite Proteomics, LLCWhat the filing says"On March 11, 2026, the Company completed the acquisition described in Item 1.01 above." | Aditxt, Inc. | $36M | SEC 8-KFiled by the buyer |
| 2026-02-26 | Niagen Bioscience, Inc. (NAGE) | ChromaDex Reference Standards businessWhat the filing says"Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces the sale of its ChromaDex Reference Standards business to LGC, as of February 24, 2026, in an all-cash transaction." | LGC | Not disclosed | SEC 8-K exhibit |
| 2026-02-09 | Becton, Dickinson and Company (BDX) | BD Biosciences and Diagnostic Solutions businessWhat the filing says"On February 9, 2026 (the "Closing Date"), Waters Corporation, a Delaware corporation ("Waters"), and Becton, Dickinson and Company, a New Jersey corporation ("BD"), announced that they consummated the previously announced spin-off of BD's Biosciences and Diagnostic Solutions business (the "SpinCo Business") and combination of the SpinCo Business with Waters." | Waters Corporation | Not disclosed | SEC 8-KFiled by the buyer |
| 2026-02-02 | COMMUNITY HEALTH SYSTEMS INC (CYH) | Tennova Healthcare - ClarksvilleWhat the filing says"On February 1, 2026, CHS/Community Health Systems, Inc. ("CHS"), a wholly-owned subsidiary of Community Health Systems, Inc. (the "Company"), and a subsidiary of CHS (the "CHS Selling Entity"), completed the transactions contemplated by that certain purchase agreement dated as of October 30, 2025 (the "Purchase Agreement"), with Vanderbilt University Medical Center and certain of its subsidiaries (collectively, the "Purchaser"), Clarksville Health System, G.P., and Clarksville Physician Services, G.P. (Clarksville " | Vanderbilt University Medical Center | $623M | SEC 8-K |
| 2026-01-16 | AGENUS INC (AGEN) | Agenus manufacturing operations (Agenus West)What the filing says"As previously disclosed, on June 3, 2025, Agenus Inc. (the "Company") and its wholly-owned subsidiary Agenus West, LLC ("Agenus West" and together with the Company, "Agenus") entered into an Asset Purchase Agreement (the "Purchase Agreement") with Zydus Pharmaceuticals (USA) Inc. (subsequently assigned to Zydilac Bio, LLC, "Zydus"), a wholly-owned subsidiary of Zydus Lifesciences Limited, for the sale to Zydus of substantially all of the assets comprising Agenus' manufacturing operations run primarily through Agenu" | Zydus Lifesciences Limited | $75M | SEC 8-K |
Every sector, by size and month: divestitures in 2026.
38 healthcare divestitures in 2025.
| Filed | Seller | Business sold | Buyer | Disclosed value | Filing |
|---|---|---|---|---|---|
| 2025-12-31 | OWENS & MINOR INC/VA/ (OMI) | Owens & Minor Products & Healthcare Services businessWhat the filing says"On December 31, 2025 (the " Closing Date "), Owens & Minor, Inc., a Virginia corporation (the " Company "), completed its previously announced sale of its P&HS business (as defined below) pursuant to the Equity Purchase Agreement (the " Purchase Agreement "), by and among the Company, Dominion Healthcare Acquisition Corporation, a Delaware corporation (the " Purchaser "), and Dominion Healthcare Holdings, L.P., a Delaware limited partnership (" Purchaser Parent ")." | Platinum Equity | $375M | SEC 8-K |
| 2025-12-30 | Advanced Biomed Inc. (ADVB) | Advanced Biomed (HK) LimitedWhat the filing says"All intellectual property owned by the Hong Kong subsidiary, including intellectual property owned by Shanghai Sglcell Biotech Co., Ltd., a wholly owned subsidiary of the Hong Kong subsidiary, was transferred to the Buyer at the closing of this transaction on December 23, 2025." | Wei Ha Hui | $20K | SEC 8-K exhibit |
| 2025-12-03 | Xtant Medical Holdings, Inc. (XTNT) | Xtant Coflex/CoFix product line and Paradigm Spine GmbHWhat the filing says"On December 1, 2025, Xtant Medical Holdings, Inc. (the "Company") and Surgalign SPV, Inc., a wholly owned subsidiary of the Company (together with the Company, the "Seller"), completed the sale of certain assets relating to the Company's Coflex and CoFix products (the "Coflex/CoFix Divestiture") to Companion Spine, LLC and one of its affiliates, Companion Spine SAS ("Companion Spine"), pursuant to the previously disclosed Asset Purchase Agreement dated July 7, 2025 between the Seller and Companion Spine (the "Cofle" | Companion Spine, LLC | $19.2M | SEC 8-K |
| 2025-12-02 | COMMUNITY HEALTH SYSTEMS INC (CYH) | Community Health Systems ambulatory outreach businessWhat the filing says"On December 1, 2025, CHS/Community Health Systems, Inc. ("CHS"), a wholly-owned subsidiary of Community Health Systems, Inc. (the "Company"), completed the transactions contemplated by that certain asset purchase agreement dated as of July 22, 2025, as amended (the "Purchase Agreement"), with Laboratory Corporation of America Holdings (the "Purchaser"), the entry into which Purchase Agreement was previously disclosed on a Current Report on Form 8-K filed by the Company on July 22, 2025." | Laboratory Corporation of America Holdings | $194M | SEC 8-K |
| 2025-11-10 | Mallinckrodt plc | Spin-off: Par Health, Inc.What the filing says"Mallinckrodt plc ("Mallinckrodt") today announced the completion of the planned spin-off of its Par Health generic pharmaceuticals and sterile injectables businesses." | Not named in this filing | Not disclosed | SEC 8-K exhibit |
| 2025-11-07 | Biofrontera Inc. (BFRI) | Xepi (ozenoxacin) cream product assetsWhat the filing says"WOBURN, Mass. (November 7, 2025) - Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company") , a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced that it has divested its US license for Xepi ® (ozenoxacin) Cream, 1% to Pelthos Therapeutics Inc. Biofrontera received $3 million at closing, and is to receive an additional $1 million upon availability of commercial product, and up to $6 million in milestone payments, with $3 million ea" | Pelthos Therapeutics Inc. | $3M | SEC 8-K exhibit |
| 2025-11-06 | BIOLIFE SOLUTIONS INC (BLFS) | evo, a cold chain logistics subsidiary operated under SAVSU Cleo Technologies, LLCWhat the filing says"On October 6, 2025, we completed the sale of evo, a previously wholly owned cold chain logistics subsidiary operated under SAVSU Cleo Technologies, LLC (formerly known as SAVSU Technologies, Inc.), for an aggregate sales price of $25.5 million in cash" | Not named in this filing | $25.5M | SEC 8-K exhibit |
| 2025-11-04 | LifeMD, Inc. (LFMD) | WorkSimpli Software LLCWhat the filing says"LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual healthcare services and pharmacy, today announced the sale of its majority ownership interest in WorkSimpli Software LLC ("WorkSimpli") in a transaction valuing WorkSimpli at an enterprise value of approximately $65 million." | Lion Buyer, LLC | $24M | SEC 8-K exhibit |
| 2025-10-23 | SciSparc Ltd. (SPRC) | MitoCareX Bio Ltd.What the filing says"At the Closing, each of the Sellers transferred their Ordinary Shares to N2OFF, thereby resulting in N2OFF holding 100% of the fully-diluted share capital of MitoCareX and, as consideration thereof, N2OFF: (1) executed the payment of $700,000 in cash to SciSparc, and (2) completed the following issuances of common stock to each of the Sellers: ● 490,751 shares of common stock to SciSparc, representing 16.75% of the Company on a fully-diluted basis; ● 454,127 shares of common stock to Alon, representing 15.50% of th" | N2OFF, Inc. | Not disclosed | SEC 8-KFiled by the buyer |
| 2025-10-07 | ELUTIA INC. (ELUT) | Elutia CIED BusinessWhat the filing says"Closing of Sale of CIED Business As previously reported, on September 8, 2025, Elutia and Elutia Med (collectively, the " Sellers ") executed the Purchase Agreement with the Buyers." | Boston Scientific Corporation | $88.3M | SEC 8-K |
| 2025-10-02 | UnitedHealth Group Incorporated and Amedisys, Inc. | UnitedHealth and Amedisys home health and hospice operations in Tennessee, Georgia and AlabamaWhat the filing says"Pennant Completes Purchase of Tennessee, Georgia and Alabama Operations from UnitedHealth Group and Amedisys EAGLE, Idaho, October 2, 2025 - The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, announced today that on October 1, 2025, it acquired certain operations from UnitedHealth Group Incorporated ("UnitedHealth")." | The Pennant Group, Inc. | $147M | SEC 8-K exhibitFiled by the buyer |
| 2025-09-23 | MASIMO CORP (MASI) | Sound UnitedWhat the filing says"Masimo (Nasdaq: MASI) today announced it has completed the previously announced sale of its Sound United consumer audio business to HARMAN International ("HARMAN"), a wholly-owned subsidiary of Samsung Electronics Co., Ltd. Katie Szyman, Chief Executive Officer of Masimo, stated, "The completion of the Sound United sale is an important milestone in our ongoing efforts to focus on our core professional healthcare business." | Harman International Industries, Incorporated | $350M | SEC 8-K exhibit |
| 2025-09-16 | HWH International Inc. (HWH) | Alset F&B One Pte. Ltd.What the filing says"The sale of shares of Alset F&B One pursuant to the Sale and Purchase Agreement was completed on September 10, 2025." | Alset International Limited | $170K | SEC 8-K |
| 2025-09-05 | FIBROGEN INC (FGEN) | FibroGen International (Hong Kong) Ltd.What the filing says"This Current Report on Form 8-K is being filed in connection with the completion on August 29, 2025, or the closing (the "Closing"), of the transaction contemplated by the Share Purchase Agreement, dated February 20, 2025, and entered into with AstraZeneca Treasury Limited ("AstraZeneca") pursuant to which we and our indirect subsidiary FibroGen China Anemia Holdings, Ltd. sold all of the issued and outstanding equity interests of FibroGen International (Hong Kong) Ltd. to AstraZeneca, for approximately $220 millio" | AstraZeneca Treasury Limited | $220M | SEC 8-K |
| 2025-09-02 | Solventum Corp (SOLV) | Solventum Purification & Filtration businessWhat the filing says"Solventum (NYSE: SOLV) today announced it has completed the sale of its Purification & Filtration business ("P&F") to Thermo Fisher Scientific Inc. (NYSE: TMO) ("Thermo Fisher") for $4.0 billion in cash before customary adjustments." | Thermo Fisher Scientific Inc. | $4bn | SEC 8-K exhibit |
| 2025-07-31 | Adaptimmune Therapeutics PLC (ADAP) | Adaptimmune cell therapy business (TECELRA, lete-cel, afami-cel and uza-cel)What the filing says"On July 31, 2025, Adaptimmune Limited ("Seller", a wholly-owned subsidiary of the Company and, together with the Company, "Adaptimmune"), completed the sale of the assets and rights related to Adaptimmune's TECELRA, lete-cel, afami-cel and uza-cel cell therapies to USWM CT, LLC, a subsidiary of US WorldMeds Partners, LLC (such sale, the "Transaction")." | US WorldMeds Partners, LLC | $55M | SEC 8-K |
| 2025-07-22 | Life Healthcare Group | Life Molecular Imaging LimitedWhat the filing says"Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D BEDFORD, Mass., July 22, 2025 - Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), today announced the successful completion of its previously disclosed acquisition of Life Molecular Imaging Ltd. ("Life Molecular"), a subsidiary of Life Healthcare Group Holdings Ltd ("Life Healthcare")." | Lantheus Holdings, Inc. | $350M | SEC 8-K exhibitFiled by the buyer |
| 2025-07-01 | COMMUNITY HEALTH SYSTEMS INC (CYH) | Cedar Park Health System, L.P.What the filing says"On June 30, 2025, CHS/Community Health Systems, Inc. ("CHS"), a wholly-owned subsidiary of Community Health Systems, Inc. (the "Company"), and certain subsidiaries of CHS (the "CHS Selling Entities"), completed the transactions contemplated by that certain purchase agreement dated as of April 15, 2025, as amended (the "Purchase Agreement"), with subsidiaries of Ascension Health (the "Purchaser"), and Cedar Park Health System, L.P. (the "Joint Venture"), the entry into which Purchase Agreement was previously disclos" | Ascension Health | $436M | SEC 8-K |
| 2025-06-30 | ALTEROLA BIOTECH INC. | Phytanix BioWhat the filing says"On May 16, 2025, Alterola, EMC2, and the Preferred Stockholders completed its business combination with Protagenic." | Protagenic Therapeutics, Inc. | Not disclosed | SEC 8-K |
| 2025-06-13 | Cryoport, Inc. (CYRX) | CRYOPDP BusinessWhat the filing says"On June 11, 2025 (the "Closing Date"), Cryoport, Inc. (the "Company", and collectively with certain of its wholly owned subsidiaries, "Sellers") completed the previously announced disposition of its CRYOPDP Business, an operating segment within its Life Sciences Services reportable segment, to designated affiliates of DHL Supply Chain International Holding B.V. ("Purchaser") pursuant to the Sale and Purchase Agreement dated as of March 31, 2025 (the "Agreement")." | DHL Supply Chain International Holding B.V. | $200M | SEC 8-K |
| 2025-06-13 | Healthtech Solutions, Inc./UT | World Reach Holdings, LLCWhat the filing says"Healthtech Solutions, Inc., a Utah corporation (the "Company"), World Reach Holdings, LLC, a Delaware limited liability company and a majority-owned subsidiary of the Company ("WR Holdings"), World Reach Health LLC, a Delaware limited liability company and a wholly-owned subsidiary of WR Holdings ("WRH"; and together with WR Holdings, the "World Reach Companies"), Healthtech Wound Care, Inc., a Delaware corporation and a majority-owned subsidiary of the Company ("HTWC"), and World Reach Med, LLC, a Delaware limited" | Papyrus Distribution LLC | Not disclosed | SEC 8-K |
| 2025-06-12 | Body and Mind Inc. | NMGWhat the filing says"On June 6, 2025, pursuant to the previously disclosed Amended MIPA between Fox Farms, DEP and NMG, dated January 3, 2025, DEP assigned, sold and transferred all of the issued and outstanding membership interests in NMG to Fox Farms as all of the closing conditions have been satisfied or expressly waived and NMG received regulatory approval by the Nevada Cannabis Compliance Board approving the change in ownership of NMG and the commercial cannabis cultivation distribution and manufacturing licenses held by NMG from " | Fox Farms | $400K | SEC 8-K |
| 2025-06-02 | Pivot Occupational Health, LLC | Onsite Innovations, LLCWhat the filing says"Effective June 1, 2025, Concentra Health Services, Inc. ("CHS"), a wholly owned subsidiary of Concentra Group Holdings Parent, Inc. (the "Company"), consummated the previously announced acquisition of Onsite Innovations, LLC ("Onsite Innovations"), pursuant to the terms of an equity purchase agreement, dated April 18, 2025 (the "Purchase Agreement"), by and between CHS and Pivot Occupational Health, LLC (the "Seller")." | Concentra Group Holdings Parent, Inc. | $55M | SEC 8-KFiled by the buyer |
| 2025-04-14 | Coherus BioSciences, Inc. (CHRS) | UDENYCA franchiseWhat the filing says"NASDAQ: CHRS) today announced the completion of the previously announced divestiture of its UDENYCA (pegfilgrastim-cbqv) franchise (the Transaction) to Intas Pharmaceuticals Ltd. (Intas) pursuant to the asset purchase agreement (the Agreement) dated December 2, 2024 between Coherus and Intas in a deal valued at up to $558.4 million." | Intas Pharmaceuticals Ltd. | $483M | SEC 8-K exhibit |
| 2025-04-01 | COMMUNITY HEALTH SYSTEMS INC (CYH) | Lake Norman Regional Medical CenterWhat the filing says"On April 1, 2025, CHS/Community Health Systems, Inc. ("CHS"), a wholly-owned subsidiary of Community Health Systems, Inc. (the "Company"), completed the transactions contemplated by that certain asset purchase agreement dated as of December 11, 2024 (the "Purchase Agreement"), with Duke University Health System, Inc. (the "Purchaser"), the entry into which Purchase Agreement was previously disclosed on a Current Report on Form 8-K filed by the Company on December 11, 2024." | Duke University Health System, Inc. | $284M | SEC 8-K |
| 2025-03-26 | Whitehawk Therapeutics, Inc. (AADI) | Aadi Subsidiary, Inc.What the filing says"On March 25, 2025, Whitehawk Therapeutics, Inc. (the " Company ") completed its previously announced sale of 100% of the outstanding shares of capital stock of Aadi Subsidiary, Inc. (the " Divestiture ") pursuant to the Stock Purchase Agreement (the " Purchase Agreement ") entered into with KAKEN INVESTMENTS INC., a Delaware corporation (" Purchaser "), KAKEN PHARMACEUTICAL CO., LTD, and Aadi Subsidiary, Inc. on December 19, 2024." | Kaken Pharmaceutical Co., Ltd. | $102M | SEC 8-K |
| 2025-03-11 | Anika Therapeutics, Inc. (ANIK) | Parcus Medical, LLCWhat the filing says"Parcus Medical Sale Completed The sale of Parcus Medical to Medacta Group SA closed today, March 7, 2025 for an undisclosed amount." | Medacta Group SA | $4.5M | SEC 8-K exhibit |
| 2025-03-03 | COMMUNITY HEALTH SYSTEMS INC (CYH) | ShorePoint Health Port Charlotte and Punta Gorda facilitiesWhat the filing says"On March 1, 2025, CHS/Community Health Systems, Inc. ("CHS"), a wholly-owned subsidiary of Community Health Systems, Inc. (the "Company"), and certain wholly-owned subsidiaries of CHS (the "CHS Selling Entities"), completed the transactions contemplated by that certain asset purchase agreement dated as of November 22, 2024 (the "Purchase Agreement"), with Adventist Health System Sunbelt Healthcare Corporation and certain of its affiliates (collectively, "Purchaser"), the entry into which Purchase Agreement was prev" | Adventist Health System Sunbelt Healthcare Corporation | $260M | SEC 8-K |
| 2025-02-03 | BAXTER INTERNATIONAL INC (BAX) | Vantive Health LLCWhat the filing says"On January 31, 2025 (the " Closing Date "), Baxter International Inc. (the " Company ") completed the previously announced sale of all issued and outstanding equity interests of Vantive Health LLC, a Delaware limited liability company (the " KidneyCo "), Vantive Mexico LLC, a Delaware limited liability company (the " US-Mexico Holdco "), Gambro Renal Products, Inc., a Delaware corporation (the " Gambro Subsidiary "), RTS Worldwide Holdings Inc., a Delaware corporation (the " RTS Holdco " and, together with KidneyCo" | CP Spruce Holdings, S.C.Sp | $3.8bn | SEC 8-K |
| 2025-02-03 | CareMax, Inc. (CMAXQ) | CareMax core centers businessWhat the filing says"The acquisition of the Core Centers Assets by the Buyer closed on February 3, 2025." | ClareMedica Parent Holdings, LP | $100M | SEC 8-K |
| 2025-01-23 | NovaBay Pharmaceuticals, Inc. (NBY) | Avenova eyecare businessWhat the filing says"On January 17, 2025, NovaBay Pharmaceuticals, Inc. (the "Company") completed the sale (the "Asset Sale Transaction") of its eyecare products sold under the Avenova brand and related assets (the "Avenova Assets") to PRN Physician Recommended Nutriceuticals, LLC ("PRN"), which constituted substantially all of the Company's revenue generating and operating assets." | PRN Physician Recommended Nutriceuticals, LLC | $11.5M | SEC 8-K |
| 2025-01-23 | ProPhase Labs, Inc. (PRPH) | Pharmaloz Manufacturing, Inc. and Pharmaloz Real Estate Holdings, Inc.What the filing says"The transaction closed concurrently with the execution of the Agreement on January 16, 2025." | JL Projects, Inc. | Not disclosed | SEC 8-K |
| 2025-01-17 | PMGC Holdings Inc. (ELAB) | Elevai Skincare skincare and haircare businessWhat the filing says"On January 16, 2025, PMGC Holdings Inc. (the "Company") and its wholly owned subsidiary, Elevai Skincare Inc. (the "Seller"), completed the previously announced disposition of substantially all of the assets (the "Disposed Assets") and assignment of certain of the liabilities (the "Assumed Liabilities") of the Seller, related to the Seller's skincare and haircare business (the "Disposition"), pursuant to an Asset Purchase Agreement dated as of December 31, 2024 (the "Purchase Agreement"), by and among the Company, " | Carmell Corporation | $1.4M | SEC 8-K |
| 2025-01-07 | LUDWIG ENTERPRISES, INC. (LUDG) | Exousia Ai, Inc.What the filing says"On January 1, 2025, the closing under the Exousia SPA was completed." | Marijuana, Inc. | $500K | SEC 8-K |
| 2025-01-03 | Bioventus Inc. (BVS) | Bioventus Advanced Rehabilitation businessWhat the filing says"Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, announced today that it has successfully completed the divestiture of its Advanced Rehabilitation business to Accelmed Partners ("Accelmed"), a private equity firm focused on acquiring and growing commercial-stage HealthTech companies." | Accelmed Partners | $25M | SEC 8-K exhibit |
| 2025-01-03 | NU SKIN ENTERPRISES, INC. (NUS) | Mavely LLCWhat the filing says"As part of the transaction, Rhyz sold its Mavely affiliate marketing technology platform to Later in exchange for approximately $250 million in the form of cash and a minority equity stake in the combined Later/Mavely business." | Clout.io Holdings, Inc. | $250M | SEC 8-K exhibit |
| 2025-01-03 | VERU INC. (VERU) | Veru FC2 female condom businessWhat the filing says"Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that it has sold its FC2 Female Condom® (Internal Condom) business to clients managed by Riva Ridge Capital Management LP, a New York City-based investment management firm as well as other co-investors, for $18 million, subject to adjustment as set forth in the purchase" | Clear Future, Inc. | $18M | SEC 8-K exhibit |
| 2025-01-02 | Avamere Home Health Care, LLC | Signature Healthcare at Home Oregon operationsWhat the filing says"Pennant Completes Acquisition of Signature Healthcare at Home Assets EAGLE, Idaho, January 2, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today announced that it has closed on the purchase of certain Oregon assets of Signature Healthcare at Home ("Signature")." | The Pennant Group, Inc. | $48.5M | SEC 8-K exhibitFiled by the buyer |
Every sector, by size and month: divestitures in 2025.
More than one healthcare divestiture.
Healthcare carve-outs in your inbox every Wednesday.
One email a week with the completed divestitures and spin-offs from SEC 8-K filings that match your sectors and deal size, each with the filing. A private page holds the full history with a CSV. From $1,500 a year.
Looking to buy carve-outs?
Register your thesis: sectors, size and geography. When a divestiture mandate we take to market fits it, a senior advisor on our team contacts you under NDA. No fee.
What counts, and where it comes from.
A row is a completed sale or spin-off of a business unit (a business, segment, division or named subsidiary) reported in a Form 8-K filed with the SEC during the month (or, on a weekly page, the ISO week, Monday to Sunday): under Item 2.01, completion of acquisition or disposition of assets, or in a press release attached to the filing that says the sale has closed.
Sales of buildings, loan books or securities are left out, as is the sale of a whole company. Seller, buyer and value come from the filing, and each row keeps a sentence from it and a link to it. Where a filing does not name the buyer or the price, the table says so rather than filling the gap. The sector is the seller's SEC industry code, not the unit's; where the seller has none (a private or foreign parent, named in a filing made by the buyer), it is the sector of the business sold.
Weekly pages start in September 2026. The months from January 2025 to April 2026, and some deals in later months, were added in October 2026 from every Item 2.01 filing in that window, read and classified by hand rather than by the weekly search. Deals a seller reported only in a quarterly results release or another press release were read and added by hand as well.
Source: SEC EDGAR full-text search and the filings themselves. Public filings only. None of these transactions is one of our mandates, and nothing here is advice.
Planning a carve-out of your own?
The filings show what closed. The work that decides the price happens months earlier: the perimeter, the standalone numbers and the transition services.
Every mandate startswith one conversation.
Tell us what you are considering. A senior advisor on our team will come back with a straight read on value, timing and who would actually buy it, before you commit to anything.
- Confidential. Nothing you share leaves the advisory team.
- Success-based. No retainer, no upfront fees, no obligation.
- A senior advisor on our team responds within one business day.